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Abstract  
Insulin is a major autoantigen in type 1 diabetes, targeted by both CD8 and CD4 T-cells. We 
studied an insulin-reactive T-cell receptor (TCR) alpha-chain transgenic non-obese diabetic 
(NOD) mouse on a TCRCȽ and proinsulin2 (PI2)-deficient background, designated as 
A22Cα-/-PI2-/-NOD mice.  These mice develop a low incidence of autoimmune diabetes.  To 
test the role of gut microbiota on diabetes development in this model system, we treated the 
A22Cα-/-PI2-/-NOD mice with enrofloxacin, a broad-spectrum antibiotic.  The treatment led to 
male mice developing accelerated diabetes.  We found that enrofloxacin increased the 
frequency of the insulin-reactive CD8+ T-cells and activated the cells in the Peyer’s patches 
(PP) and pancreatic lymph nodes (PLNs), together with induction of immunological effects 
on the antigen-presenting cell populations.  The composition of gut microbiota differed 
between the enrofloxacin-treated and untreated mice and also between the enrofloxacin-
treated mice that developed diabetes, compared with those that remained normoglycemic.  
Our results provide evidence that the composition of the gut microbiota is important for 
determining the expansion and activation of insulin-reactive CD8+ T-cells. 
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Introduction   
 
The incidence of type 1 diabetes (T1D) is increasing worldwide, at a rate too rapid to be 
associated purely with genetic changes (1), and thus environmental factors, such as the gut 
microbiota, have been suggested to contribute to T1D development (2).  The gut microbiota 
composition (3-5) and function (6) are altered in patients with T1D.  In the Non-obese 
diabetic (NOD) mouse model, which develops spontaneous autoimmune diabetes similar to 
humans, altered gut microbiota are also found in the diabetic NOD mice, compared to non-
diabetic NOD mice (7).  Modifying the gut microbiota by fecal transfer studies (8), dietary 
changes (9; 10) and the administration of antibiotics (dependent on type, age at which 
administered and duration) (11-17), all affect diabetes development in NOD mice.  Recently, 
we have shown that islet-specific glucose-6-phosphatase catalytic subunit-related protein-
reactive (IGRP) CD8+T-cells can recognize a fusobacterial peptide more strongly than their 
natural autoantigen (18), suggesting that islet autoimmunity can be activated by molecular 
mimicry.  Furthermore, microbial metabolites released from the diet protect NOD mice by 
reducing the number of IGRP-reactive CD8+T-cells (10).  Interestingly, the development of 
IGRP-reactive CD8+T-cells is dependent on prior insulin autoimmunity (19; 20).  
Proinsulin (PI) is a major autoantigen in humans (21-25) and NOD mice (26-30).  Proinsulin 
is cleaved within the pancreatic beta cells, leading to the regulated secretion of 
metabolically-active insulin.  There are 2 forms of PI in mice, designated PI1 and PI2.  PI2 is 
expressed both in the thymus and pancreas and PI2-deficient mice NOD mice developed 
accelerated diabetes with 100% penetrance (31), and thus PI2 is considered to be important 
in the induction of T-cell tolerance.   
 4 
G9C8 is a highly diabetogenic murine CD8+T-cell clone that recognizes insulin B15-23 
through its T-cell receptor (TCR) comprising TCRα chain (TRAV8-1/TRAJ9) and TCRβ 
chain (TRBV19/TRBJ2-3) gene rearrangements (32).  G9C8 CD8+T-cells can be found in the 
islets in 4-week-old mice (29), along with other insulin-specific T cells, before islet antigen-
specific T-cells of other specificities are detected (33) and are required for the development 
of other autoantigen-specific CD8+ T-cells (19; 20).  We previously generated a transgenic 
NOD mouse (line 22) with a fixed TRAV8-1/TRAJ9 TCRα-chain only (29) (termed A22 for 
simplicity).  A22 mice were bred to the PI2-deficient background to study the development 
and activation of insulin B15-23-reactive CD8+T-cells (34).  We found that the PI2-deficient 
A22Cα-/-NOD mice had an increased proportion of insulin B15-23-reactive CD8+ T-cells in 
the pancreatic draining lymph nodes (PLN), compared to A22Cα-/-NOD mice that have 
normal levels of PI2.  Furthermore, only male, but not female, PI2-deficient A22Cα-/-NOD 
mice (A22Cα-/-PI2-/-NOD) developed spontaneous diabetes.  
In this study, by changing the gut microbiota, we have demonstrated that a broad-spectrum 
antibiotic enrofloxacin (Baytril) can alter insulin-specific CD8+T-cell function and enable 
them to expand and become activated, leading to an early onset of diabetes, in A22Cα-/-PI2-/-
NOD mice.   
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Materials and methods  
Mice 
NOD/Caj mice were originally obtained from Yale University.  G9Cα-/-NOD, G9Cα-/-PI2-/-
NOD and A22Cα-/-PI2-/-NOD have all been previously described and are summarized in 
Supplementary Table 1 (34-36). All mice used in the current study were male, from litters 
divided between treatment groups (Fig.1A).  Mice from several breeder pairs were mixed 
and housed in microisolators or scantainers with food and water ad libitum, with 12-hour 
light and dark cycles in the specific pathogen-free facility at Cardiff University.  All 
procedures were performed in accordance with UK Home Office approved protocols. 
 
Preparation and administration of enrofloxacin-treated water 
Enrofloxacin (Bayer) was added to autoclaved, filtered water at a final concentration of 
0.4mg/ml (diluted 1:250), prepared freshly every week.  Untreated mice received the same 
autoclaved, filtered water.  Mice were treated from 3-weeks of age (at weaning) continuously 
until 10-weeks of age, unless otherwise stated. 
 
Diabetes Incidence 
Mice were monitored weekly for glycosuria (Bayer Diastix) from 5-weeks of age until 
termination.  Diabetes was diagnosed after 2 consecutive positive glycosuria tests, confirmed 
by a blood glucose concentration >13.9mmol/L (>250mg/dl).  Statistical analysis was 
performed using the log-rank test. 
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Surface and Intracellular staining 
Lymphoid tissues including spleen, pancreatic lymph nodes (PLN), mesenteric lymph nodes 
(MLN) and Peyer’s patches (PP) were collected from 6-week-old or 10-week-old mice.  Cells 
were homogenized and filtered. Splenic red blood cells were lysed using water, followed by 
10xPBS.  1x106 cells were then incubated with TruStain FcX (BioLegend) in PBS+0.5% BSA 
at 4°C for 10min prior to cell staining (4°C, 30min) using combinations of the following 
monoclonal antibodies (all from BioLegend unless stated): anti-B220, anti-CD4, anti-CD8α, 
anti-CD11b, anti-CD11c, anti-CD19, anti-CD80, anti-CD103, anti-F4/80, anti-TCRbeta, anti-
TCRVbeta4, anti-TCRVbeta5.1-5.2, anti-TCRVbeta6, anti-TCRVbeta8.1-8.2 (BD), anti-
TCRVbeta12 (eBioscience), anti-TCRVbeta11 (eBioscience), anti-TCRVbeta14 (BD) and 
anti-MHCII (BD) in the presence of a viability dye (BioLegend or eBioscience). 
For Intracellular cell staining, 1-2x106 cells were incubated at 37°C in the presence of 50ng/ml 
PMA, 500ng/ml Ionomycin and 2μM Monensin (all from Sigma-Aldrich) for 4hours.  Cells 
were then stained for surface molecules prior to fixation/permeabilization and the addition of 
intracellular monoclonal antibodies (all BioLegend): anti-IFN-gamma, anti-IL-10 or anti-
FoxP3.  Cells were analyzed on a BD LSRFortessa FACS machine and subsequently analyzed 
with FlowJo software version 8.8.6.  Statistical analysis was performed by Student’s t test. 
 
Generating Tetramers 
H-2Kd-LYLVCGERG monomers or H-2Kd-AYAAAAAAV monomers (National Institutes of 
Health Tetramer Core Facility) were slowly defrosted on ice.  Tetramers were made as 
described previously (37).   
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Tetramer Staining 
Tetramer staining was conducted as previously reported (34).  G9C8 transgenic T-cells (35) 
or NY8.3 transgenic T-cells (38) were used as a positive control.  The minimal H-2Kd-
AYAAAAAAV tetramer was used to determine non-specific background, which was then 
subtracted from the H-2Kd-LYLVCGERG-Brilliant Violet 421 or H-2Kd-VYLKTNVFL-
Allophycocyanin tetramer staining result respectively.  Cells were analyzed as above.  
Statistical analysis was performed by Student's t test. 
 
Fecal bacterial extraction  
Fecal samples from 3-week and 6-week-old mice were collected.  Fecal bacteria were 
extracted and sequenced as previously described (8).  β-Diversity was calculated to compare 
differences between microbial community profiles, and the data are shown as a principal 
coordinate analysis (PCoA).  Microbial composition was analyzed by Student's t test with β-
Diversity PCoA plots analyzed by ANOSIM. 
 
In vitro antigen presentation  
CD11c+ and CD11b+ cells were isolated from the spleens of 6-week-old A22Cα-/-PI2-/-NOD 
mice untreated or treated with enrofloxacin.  CD8+T-cells were isolated by negative selection 
from the spleen of 6-week-old G9Cα-/-NOD mice. All cell isolations were conducted 
following the manufacturer's protocols (Miltenyi).  CD8+T-cells were CFSE-labeled and co-
cultured with the antigen-presenting cells (APCs) in a 1:1 ratio, for 48 hours, in the presence 
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or absence of insulin B15-23 peptide. Cells were stained for surface markers and analyzed as 
previously described.  Statistical analysis was performed by Student's t test. 
 
In vitro splenocyte:bacteria co-culture 
The small intestine was harvested from 6-week-old mice and flushed with 5mls sterile PBS.  
The gut contents were mixed thoroughly by vortex for 2mins, followed by centrifuging for 
5mins at low speed (52xg) to remove dietary residue.  The supernatant was transferred to a 
new tube and spun.  After washing the pellet twice more, the combined supernatant was 
centrifuged at 469xg to remove mammalian cells.  Bacteria in the supernatant were pelleted 
by high-speed centrifugation (1876xg, 5mins) and resuspended in PBS.  Bacterial 
concentration was measured with a spectrophotometer (Bio-Rad) and heat-inactivated at 90℃ 
for 20mins. 108 heat-inactivated bacteria were co-cultured with splenocytes (2x106/ml) for 
12hours prior to the addition of 50ng/ml PMA, 500ng/ml Ionomycin in the presence of 2μM 
Monensin (all Sigma-Aldrich).  4hours later, cells were then stained for surface and 
intracellular markers as outlined above.  Statistical analysis was performed by multiple 
Student’s t tests, corrected using FDR. 
 
Results 
Enrofloxacin treatment accelerates and increases spontaneous diabetes development in male 
PI2-deficient TRAV8-1/TRAJ9Cα-/- NOD mice 
Single TCRα chain transgenic NOD mice, utilizing the TCR TRAV8-1/TRAJ9Cα-/- 
(designated A22Cα-/-) (34), bred with PI2-deficient mice (A22Cα-/-PI2-/-), have elevated levels 
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of insulin B15-23-reactive CD8+T-cells and develop a low incidence of spontaneous 
diabetes.  To test whether the gut microbiota may influence the expansion and activation of 
insulin B15-23-reactive CD8+T-cells, as recently reported for other autoreactive T-cells (18; 
39; 40), we administered enrofloxacin (a broad-spectrum antibiotic), to either the breeder 
A22Cα-/-PI2-/-NOD mice throughout pregnancy, or to the A22Cα-/-PI2-/-NOD pups from 
weaning at 3 weeks (Fig.1A).  We found that spontaneous diabetes developed in ~50% of 
A22Cα-/-PI2-/-NOD male mice given enrofloxacin at the time of weaning, compared to 
A22Cα-/-PI2-/-NOD mice never exposed to enrofloxacin (~10%), or to A22Cα-/-PI2-/-NOD 
mice treated with enrofloxacin from birth (15%), or from birth to weaning only (0%) 
(Fig.1B).  We repeated this experiment focusing only on mice given enrofloxacin from 
weaning (enrofloxacin-treated), compared to untreated mice and again found a significant 
increase in spontaneous diabetes development in those given enrofloxacin from weaning 
(Fig.1C).  Whereas the A22Cα-/-PI2-/-NOD mice have the same TCRα chain as G9C8 
CD8+T-cells but can pair with any endogenous TCRβ chain, the G9Cα-/-PI2-/-NOD mice 
express both the rearranged G9C8TCRα and β chains.  Interestingly, unlike the effect in 
A22Cα-/-PI2-/-NOD mice, enrofloxacin did not affect the incidence of diabetes in G9Cα-/-PI2-/-
NOD mice (Fig.1D).  Thus, gut bacterial composition may alter expansion of particular TCR 
clonotypes, other than the clonotypic G9C8TCR, that recognize insulin B15-23, which we 
next investigated.  
 
Enrofloxacin treatment leads to Insulin B15-23-reactive CD8+T-cell expansion, altered TRBV 
repertoire and activation 
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All T-cells in A22Cα-/-PI2-/-NOD mice have the fixed TCR chain derived originally from a 
CD8+T-cell and thus, we investigated the effect of enrofloxacin treatment on shaping the 
CD8+T-cell compartment.  We found that in all tissues, except the Peyer’s patches (PP), 
there was an age-associated increase in CD8+T-cells, while CD4+T-cells were reduced 
(Supplementary Fig.1A-B and (34)).  No significant differences in the proportion of 
FoxP3+Tregs between enrofloxacin-treated or untreated mice were observed in the PLN 
(Supplementary Fig.1C) or PP, although there was an age-related increase in the untreated 
mice.  
To identify the insulin-specific CD8+T-cells, we used an insulin B15-23-tetramer to 
investigate if antibiotic usage affected insulin B15-23-specific CD8+T-cells in different 
lymphoid tissues.  Interestingly, our results demonstrated a significant increase in the 
proportion and number of insulin B15-23-tetramer-positive CD8+T-cells in the PLN, MLN 
and PP of both 6-week-old and 10-week-old A22Cα-/-PI2-/-NOD mice treated with 
enrofloxacin compared to the untreated mice (Fig.2A-B and Supplementary Fig.2A).  The 
expansion of these insulin-reactive CD8+T-cells was more pronounced in the 6-week-old 
mice, corresponding with the earliest development of diabetes in the enrofloxacin-treated 
mice.  Moreover, we observed an increased percentage of activated (CD69+) tetramer-
positive CD8+T-cells in the PLN and PP of 6-week-old and 10-week-old enrofloxacin-
treated mice respectively, compared to the untreated mice (Fig.2C-D and Supplementary 
Fig.2B).  We also observed that tetramer-negative CD8+CD69+T-cells were reduced in the 
PP with age in untreated mice, while they remained at a consistent proportion in 
enrofloxacin-treated mice (Supplementary Fig.2C-D).  Furthermore, we found that, in both 
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the PLN and PP of enrofloxacin-treated mice, the effector/memory (CD44+CD62L-) 
population of Insulin B15-23-tetramer-positive CD8+T-cells significantly increased with age 
(Fig.2E-F and Supplementary Fig.2E).  The opposite trend was observed in untreated mice.  
Interestingly, in tetramer-negative CD8+T-cells we observed an increased effector/memory 
population only at 10-weeks of age in enrofloxacin-treated mice vs untreated mice 
(Supplementary Fig. 2F-G).  We further analyzed TCRV usage and found changes in 
multiple TCRV chains in both the total CD8+T-cell repertoire and the insulin-specific 
CD8+T-cell repertoire from the PLN and PP (Fig.2G-H and Supplementary Fig.3-4).  
Interestingly, no significant differences were observed in the selection of TCRV6 (the chain 
used by G9C8 T-cells).  These data indicate earlier activation of the insulin-reactive CD8+T-
cells in the PLN of enrofloxacin-treated mice, as well as more highly activated insulin-
reactive CD8+T-cells, which have an altered TCR repertoire, in the PP of 10-week-old 
mice.  
 
Enrofloxacin alters antigen-presenting cells (APCs) 
To explore the mechanism by which enrofloxacin treatment led to the increase in activated 
insulin-B15-23-specific CD8+T-cells in A22Cα-/-PI2-/-NOD mice, we tested antigen-
presenting cells (APC) from the PLN and PP.  Here, we found changes in dendritic cells (DC) 
and macrophages (Fig.3A-F and Supplementary Fig.5), as was observed in other studies using 
antibiotics in wild-type NOD mice (14; 16).  CD103 is an integrin marker of migratory DCs 
(41), and influenced by microbial challenge (42).  We found a reduction in both 
CD11c+CD103+ and CD11b+CD103+cells in the PP of the enrofloxacin-treated mice at 6 
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weeks, compared to untreated mice but an increase at 10 weeks, whereas in untreated mice, 
these cells were reduced with age (Fig.3A-B).   These effects were not observed in the PLN 
(data not shown).  Moreover, the DCs and macrophages expressed increased IFN-gamma 
production, particularly in 6-week-old enrofloxacin-treated mice (Fig.3C-D).  There were also 
fewer IL-10-producing DCs, with a similar trend in the macrophages in the enrofloxacin-
treated mice, compared to control mice at 6 weeks (Fig.3E-F), although not sustained by 10 
weeks.  Although it has been suggested that CD11b+CD11c+cells are more inflammatory 
(43), we did not find any changes in CD11b+CD11c+cells nor in B-cells in the PP, including 
IgA+B-cells (Supplementary Fig.6).   
To determine whether these APC subsets were able to promote the proliferation of insulin-
reactive CD8+T-cells, CFSE-labeled G9C8 CD8+T-cells were co-cultured with CD11c+cells 
or CD11b+cells from donors treated with or without enrofloxacin in the presence of insulin 
B15-23 peptide. We found CD11c+cells but not CD11b+cells, from enrofloxacin-treated mice 
promoted the proliferation of insulin-reactive CD8+T-cells (Fig.3G-H and Supplementary 
Fig.7).  This was not due to a direct action of enrofloxacin on the cells as we tested the effect 
of enrofloxacin in cell culture and this decreased CD69 expression in T-cells at lower peptide 
concentrations compared to the effects seen in the absence of enrofloxacin but no differences 
were found in IFN-gamma secretion (Supplementary Fig.8), suggesting that the enrofloxacin 
treatment affected the APCs in the enrofloxacin-treated mice, and these played an important 
role in modifying T-cell function.  Thus enrofloxacin treatment induced a more inflammatory 
profile in some APC subsets, which could contribute to increased activation of insulin-
reactive CD8+T-cells, particularly at 6 weeks of age. 
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Enrofloxacin modifies the gut microbiota 
Enrofloxacin targets both gram-positive and gram-negative bacteria and therefore, we asked 
whether altered microbiota were driving diabetes development.  We sequenced gut 
microbiota from the fecal pellets of 3-week-old mice (pre-antibiotic treatment) and 6-week-
old mice (3 weeks after commencement of antibiotics) when most diabetes develops.  
Interestingly, α-diversity (referring to total bacterial diversity), as measured by Chao 
richness, was not altered in the enrofloxacin-treatment groups, regardless of diabetes 
development and age (Supplementary Fig.9A).  Furthermore, no significant differences in β-
diversity (differences in the bacterial composition between treated and untreated mice) were 
seen at 3 weeks of age, confirming that there was no initial pre-treatment difference in 
bacterial composition that could contribute to altered diabetes development (Supplementary 
Fig.9B).  However, we observed significant differences in 6-week-old enrofloxacin-treated 
compared with untreated mice (Fig.4A).  Further, enrofloxacin-treated mice had a decrease in 
the relative abundance of Allobaculum, Turicibacter and Bifidobacterium, but increased 
abundances of Coprococcus and Oscillospira (all at the genus level) compared to untreated 
mice (Fig.4B).  Bifidobacterium has been associated with reducing gut permeability (44) and 
Oscillospira is associated with increased gut permeability (45).  Thus, the reduced 
Bifidobacterium and increased Oscillospira induced by enrofloxacin may both promote a 
more permeable intestinal epithelial barrier in our mice.  Next, we compared the composition 
of gut microbiota in enrofloxacin-treated A22Cα-/-PI2-/-NOD mice, which did not develop 
diabetes, to those that later developed disease.  Although there were no significant 
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differences in β-diversity in 6-week-old enrofloxacin-treated mice, with or without diabetes, 
some of the samples from the diabetic mice clustered closely, whereas the others were 
scattered widely (Fig.4C).   However, there were significant differences at the genus, family 
and species level between these two groups (Fig.4D).  These included increased relative 
abundances of Adlercreutzia (genus level), Roseburia (genus level), Lachnospiraceae 
(family level) and Bacteroidetes ovatus (species level) in those mice that later developed 
diabetes, compared to those that were protected  (Fig.4D).  Our results are in line with the 
findings by Krych and colleagues, who demonstrated an increased relative abundance of 
Firmicutes (inclusive of Coprococcus, Oscillospira, Lachnospiraceae and Roseburia), 
correlated to diabetes development in wild-type NOD mice (7). 
 
Enrofloxacin-modified gut microbiota promote stronger proinflammatory immune responses 
To assess the functional effects of the microbiota induced by enrofloxacin treatment and 
diabetes development, we performed crisscross in vitro cultures of splenocytes from 6- and 
10-week-old mice, with heat-killed microbiota from enrofloxacin-treated diabetic and non-
diabetic mice, as well as from untreated non-diabetic mice (all microbiota donors were 6 
weeks old), as controls.  We also cultured splenocytes from each of the mouse groups, 
without gut bacteria, and no differences were found between any of the groups.   
Gut bacteria from the diabetic enrofloxacin-treated donors induced the highest proportion of 
IFN-gamma-producing CD8+T-cells in the splenocytes of 6- and 10-week-old untreated mice 
compared to the gut bacteria from non-diabetic enrofloxacin-treated and untreated mice 
(Fig.5A-B and Supplementary Fig.10).  Furthermore, gut bacteria from enrofloxacin-treated 
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donors, with or without diabetes, induced a greater frequency of IFN-gamma-producing 
splenocyte CD11b+cells from enrofloxacin-treated mice compared to splenocyte 
CD11b+cells from untreated mice (Fig.5C and Supplementary Fig.11).  It is interesting that 
the profile was reversed by 10 weeks of age, with the highest frequency of IFN-gamma-
producing splenocyte CD11b+cells of untreated mice, following culture with bacteria 
(Fig.5D).  We found no significant differences in the induction of IFN-gamma-producing 
splenocyte CD11c+cells of 6- or 10-week-old mice, by the different sources of bacteria 
(Fig.5E-F and Supplementary Fig.12).  Splenocyte CD11b+cells from 6-week old treated and 
10-week-old untreated mice showed the strongest inflammatory response to the gut bacteria, 
regardless of the source (Fig.5C-D).  We found no obvious changes in TGF-beta-, IL-10-, IL-
17a-, IL-12/23- and TNF-alpha-producing CD11b+CD11c+cells, B-cells or CD4+T-cells 
(data not shown).  Finally, we tested the inflammatory response of splenocytes from G9Cα-/-
NOD mice (expressing the G9C8TCR) to gut microbiota from enrofloxacin-treated and non-
treated mice.  Our results confirmed that the microbiota from enrofloxacin-treated mice were 
more proinflammatory, as significantly higher numbers of IFN-gamma-producing G9C8 
CD8+T-cells were found in response to the gut bacteria from enrofloxacin-treated mice 
compared to the G9C8 CD8+T-cells cultured with the microbiota from untreated mice 
(Fig.6A and Supplementary Fig.13A).  We also observed enhanced IFN-gamma-producing 
splenocyte CD11b+cells in response to microbiota from diabetic enrofloxacin-treated mice 
compared to bacteria from untreated mice (Fig.6B and Supplementary Fig.13B), with a 
similar trend in splenocyte CD11c+cells (Fig.6C and Supplementary Fig.13C). Together our 
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data demonstrate that enrofloxacin treatment of A22Cα-/-PI2-/-NOD mice promotes more IFN-
gamma-inducing gut microbiota.   
 
Enrofloxacin treatment of NOD mice leads to Insulin B15-23-reactive CD8+T-cell expansion and 
activation within the Peyer’s Patches 
To assess the effect of enrofloxacin treatment on insulin B15-23-reactive CD8+T-cells in a non-
TCR restricted mouse, we treated male NOD mice with/without enrofloxacin from weaning for 3 
weeks.  We found enrofloxacin treatment significantly altered the gut microbiota composition after 
3 weeks of treatment (Fig.7A-B).  However, the microbiota changes induced by enrofloxacin 
treatment were different in the NOD mice, compared to the A22Cα-/-PI2-/-NOD mice (Fig.4) likely 
due to the TCR-restriction contributing to altered microbiota composition (Supplementary Fig.14).  
We demonstrated that enrofloxacin treatment expanded the number of insulin B15-23-reactive 
CD8+T-cells within the PP (Fig. 7C and Supplementary Fig.15A-B), with a trend to an increase in 
proportion.  In addition, we also observed an increase in the MFI of the tetramer staining in the 
PLN of enrofloxacin-treated mice compared to untreated mice (Supplementary Fig.15C).  The 
number and proportion of CD69-expressing insulin-reactive CD8+T-cells was also higher in the 
PLN and PP of enrofloxacin-treated NOD mice (Fig.7D and Supplementary Fig.15D-E).  However, 
these enrofloxacin-induced changes were restricted to the insulin B15-23-reactive CD8+T-cells, as 
we found no significant differences in the proportion, number or activation of the IGRP-reactive 
CD8+T-cells (Supplementary Fig.16).  We also observed increased IFN-gamma secretion by 
CD8+T-cells, CD11c+cells and CD11b+cells in enrofloxacin-treated NOD mice compared to 
untreated mice in all tissues (Fig.7E-G and Supplementary Fig.17).  Thus, our data suggests 
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enrofloxacin treatment can promote the expansion and activation of insulin B15-23-reactive 
CD8+T-cells and IFN-gamma secretion in both TCRα-restricted and non-TCR restricted NOD 
mice. 
 
Discussion 
In this study we investigated how changing the gut microbiota, using a broad-spectrum 
antibiotic (Enrofloxacin), influenced the TCRβ repertoire, together with expansion and 
activation of insulin-reactive CD8+T-cells, thereby leading to a higher incidence of diabetes.  
Our study has demonstrated that the altered gut microbiota induced a strong IFN-gamma 
response from a number of cell types, particularly, the CD8+T-cells.  
Using a mouse model with a restricted insulin-reactive TCRα chain but polyclonal TCRβ 
chains (both insulin-reactive and non-insulin reactive), we found alterations in the TCRβ 
repertoire influenced by gut microbiota, not previously been reported in any diabetes-related 
microbiome studies.  It is known that the Treg TCR repertoire can be strongly influenced by 
the gut microbiota composition, arising from tolerogenic antigen presentation and conversion 
of T-cells into Tregs (46-48).  Our current study demonstrates that the TCR repertoire can 
clearly be influenced by altering gut microbiota through antibiotic usage, which in turn affects 
the development of diabetes.  These changes in TCR repertoire likely arise due to expansions 
of CD8+T-cells recognizing the altered microbiota composition.  Interestingly, enrofloxacin 
administration to G9C8TCRαβ mice, in which both G9TCRα and TCR were fixed, did not 
alter the incidence of diabetes.  This suggests that the altered diabetes incidence we observed 
in this study was related to the increased expansion of cells with different TCRβ chains.  It 
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also emphasizes the importance of the effect that environmental factors, such as the 
microbiota, may have on different T-cell clonotypes.  Not only is T-cell selection affected by 
the different gut microbial composition, but the antigen-specific T-cells also are more 
activated and expand to increase diabetes incidence.   
As other studies have shown, antibiotic treatment can influence the composition of gut 
microbiota (11-17).  While most of these studies investigated female NOD mice, one study 
has focused on the male NOD mice that developed diabetes (17).  It has been shown that 
hormones can influence the gut microbiota and contribute to diabetes susceptibility in NOD 
mice (49; 50).  Interestingly, we have previously shown that, in our model system, female 
A22Cα-/-PI2-/-NOD did not develop T1D (34).  Therefore, our current study was focused on 
male A22Cα-/-PI2-/-NOD mice.  It is conceivable that the microbiota in our A22Cα-/-PI2-/-NOD 
mice may also be influenced by sex hormones, and thus contribute to the dichotomy of 
diabetes development in the different sexes.  
A recent study showed that IGRP-reactive CD8+T-cells can recognize a microbial mimic (18; 
40); it is possible that insulin-reactive CD8+T-cells may also do so, as the human insulin-
reactive 1E6 clone can recognize a bacterial peptide from a common human pathogen (25).  
However, it is unknown whether the bacteria themselves can stimulate this T-cell clone in 
vivo.  Thus to date, no bacterial mimics for insulin have yet been identified that can alter 
diabetes development.  Given the ability of autoreactive CD8+T-cells to recognize a vast 
number of peptides (51), it is highly likely, there will be some insulin mimics.  It is also 
possible that the changes in the composition of gut microbiota, especially Bifidobacteria and 
Oscillospira, altered gut permeability in our mice.  Bifidobacterium can reduce gut 
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permeability (44) while Oscillospira is associated with increasing gut permeability (45).  
Although it is not currently clear which specific bacteria played the dominant role in our 
study, we present evidence that the microbiota clearly affected insulin-reactive T-cell 
development, activation, expansion and function, particularly in relation to IFN-gamma 
secretion, leading to increased incidence of diabetes.   
Our investigation of other subsets of immune cells revealed relatively small changes in non-
CD8+T-cells.  However, we found changes in macrophages and DCs within the PP and PLN 
linked to CD103 expression, as well as altered IFN-gamma and IL-10 secretion.  Furthermore, 
upon bacterial stimulation, the macrophages and DCs exhibited enhanced IFN-gamma 
secretion.  Our data suggest a direct effect of the altered composition of microbiota on 
immune cells to secrete proinflammatory cytokines.  It is interesting that age-related 
differences were observed between treatment groups e.g. enrofloxacin-treated CD11b+cells 
from 6-week old mice exposed to microbiota produced more IFN-gamma compared to 
untreated mice.  However, at 10 weeks of age, this trend was reversed.  These time-dependent 
effects may arise from changes to immune cell:microbiota interactions in vivo, and this may 
include effects from microbial changes associated with aging as well as changes to gut 
permeability.  Furthermore, we have also demonstrated that CD11c+cells from enrofloxacin-
treated mice can promote insulin-specific CD8+T-cell proliferation in vitro compared to cells 
from untreated donors.  
In conclusion, we suggest that insulin-reactive pathogenic CD8+T-cells can be activated and 
expanded by altered gut bacteria as a result of antibiotic treatment.  The altered gut microbiota 
also promote inflammatory APCs, which in turn facilitate the expansion and activation of a 
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number of different clonotypes of insulin-reactive CD8+T-cells, leading to the development 
of accelerated autoimmune diabetes, in our NOD transgenic mouse model of autoimmune 
diabetes.  We also confirmed similar effects in non-TCR transgenic NOD mice, in which we 
observed that enrofloxacin treatment promoted the expansion and activation of insulin-
reactive CD8+T-cells, as well as promoting IFN-gamma secretion.  Our study provides 
evidence that the gut microbiota play an important role in activating the insulin-specific 
autoimmune response early in life, which then later affects diabetes development.   
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Figure Legends 
Figure 1 
Experimental design and spontaneous diabetes development. A; The experimental schema of 
enrofloxacin treatment, whereby A22Cα-/-PI2-/-NOD breeder mice (10 different breeder pairs 
were used) were either enrofloxacin-treated (top) or untreated (bottom).  A22Cα-/-PI2-/-NOD 
litters from these breeders were then randomly chosen and equally divided into enrofloxacin-
treated or untreated groups to minimize any breeder effects. B; Diabetes incidence between 
different enrofloxacin treatment regimens of A22Cα-/-PI2-/-NOD mice outlined in A. C; 
Diabetes incidence of enrofloxacin-treated (from weaning) or untreated mice A22Cα-/-PI2-/-
NOD mice. D; Diabetes incidence of enrofloxacin-treated (from weaning) or untreated G9Cα-
/-PI2-/-NOD mice.  Black arrows indicate the time of weaning. Statistical analysis was 
performed using log-rank test.  
 
Figure 2 
Insulin B15-23 T cells are increased in number and activation with Enrofloxacin treatment.  
A-B; Frequency and absolute number of Insulin B-15-23-reactive CD8+T-cells gated from 
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live single TCRβ+CD4-CD19-CD11b-CD11c- cells.  C & D; Frequency of CD69+ Insulin B-
15-23-reactive CD8+T-cell population from the PLN (C) and PP (D).  Cells were gated as in 
(A-B) prior to subsequently gating on CD69.  E & F; Frequency of CD44+CD62L- 
expressing Insulin B-15-23-reactive CD8+T-cells in the PLN (E) and PP (F).  Cells were 
gated as in (A-B), prior to subsequently gating by CD44 and CD62L expression. G-H; 
Frequency of TCR chains expressed by Insulin B-15-23-reactive CD8+T-cells in 6-week 
old A22Cα-/-PI2-/-NOD mice by enrofloxacin treatment (n=7-10) in the PLN (G) and PP (H).  
All statistical analyses were conducted using a Student’s t test.  Data are presented as mean ± 
SEM. 
 
Figure 3 
Direct ex vivo assessment of antigen presenting cell phenotype in untreated and enrofloxacin-
treated A22Cα-/-PI2-/-NOD mice.  CD11c+cells or CD11b+cells were isolated from the spleen 
of enrofloxacin-treated or untreated A22Cα-/-PI2-/-NOD mice and co-cultured in vitro with 
CFSE-labeled G9CD8+T-cells for 72 hours in the presence of insulin B15-23 peptide. A; 
Frequency of CD11c+CD103+cells gated from live single CD19-TRBV-MHCII+CD11b-
F480-cells. B; Frequency of CD11b+CD103+cells gated from live single CD19-TCRβ-
MHCII+CD11c-F480+cells. IFN-gamma (C) and IL10 (E) were assessed in CD11c+ cells 
gated from live single CD19-TCRβ-MHCII+CD11b-F480-cells. IFN-gamma (D) and IL10 
(F) were assessed in CD11b+ cells gated from live single CD19-TCRβ-MHCII+CD11c-
F480+cells. All cells shown in A-F were from Peyer’s patches.  G-H; CFSE-labeled G9 
CD8+T-cells were co-cultured with CD11c+ cells (G) or CD11b+ cells (H) (from 
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enrofloxacin-treated or untreated A22Cα-/-PI2-/-NOD mice) in a 1:1 ratio in the presence or 
absence of Insulin B15-23 peptide for 48 hours.  Data shown were corrected for background 
(cells co-cultured without peptide).  All statistical analyses were conducted using a Student’s 
t test. All data were pooled from 2 independent experiments; n=10.  Data are presented as 
mean with SEM. ND (not detected). 
 
 
Figure 4 
Altered microbial composition in A22Cα-/-PI2-/-NOD mice by enrofloxacin treatment and 
diabetes development.  A; Principal Component of Analysis (PCoA) plot of β-diversity from 
fecal bacteria of 6-week old A22Cα-/-PI2-/-NOD mice that were untreated (n=29) or treated 
with enrofloxacin (n=35) B; Altered microbiota composition expressed as a percentage of 
relative abundance of bacterial genus. All bacteria belong to the Firmicutes phylum except 
Bifidobacterium, which belongs to the phylum, Actinobacteria.  C; PCoA plot of β-diversity 
from fecal bacteria of 6-week old A22Cα-/-PI2-/-NOD mice treated with enrofloxacin that 
were non-diabetic, (n=25), or diabetic, (n=10) by the end of the observation period (10 weeks 
of age).  D; Altered microbiota composition expressed as a percentage of relative abundance 
from the genus level except Bacteroides ovatus (species level) and Lachnospiraceae (family 
level).  Lachnospiraceae and Roseburia (a member of Lachnospiraceae) are both members of 
the Firmicutes phylum; Bacteroides ovatus belongs within the Bacteroidetes phylum, while 
Adlercreutzia belongs within the Actinobacteria phylum.  Analysis of similarities (ANOSIM) 
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was used to analyze -diversity of taxonomic families of gut microbiota (A & C).  B & D 
were assessed for statistical significance using a Student's t test. 
 
Figure 5 
Effect of culture of A22Cα-/-PI2-/-NOD mice splenocytes with small intestinal bacteria from 
untreated or Enrofloxacin-treated mice.  Intracellular IFN-gamma was investigated in 
CD8+T-cells (A-B; gated from TCRβ+CD19-CD4); CD11b+cells (C-D; gated from TCRβ-
CD19-IAg7+CD11c-F480+) and CD11c+cells (E-F; gated from TCRβ-CD19-IAg7+CD11b-
F480-). Splenocyte donors were studied at both 6- (A, C, E) and 10-weeks of age (B, D, F). 
Average baseline levels of splenocyte IFN-gamma-producing cells, cultured without bacteria, 
were similar in all treatment groups are shown by the dotted line.  The black bars represent 
splenocytes from non-Enrofloxacin-treated mice, while the grey bars represent splenocytes 
from the Enrofloxacin-treated mice. The labeling beneath the graphs represent the origin of 
the bacteria - Bacteria from Non-Enrofloxacin treated mice labeled as Non-Enrofloxacin-
treated bacteria, bacteria from non-diabetic Enrofloxacin-treated mice labeled as 
Enrofloxacin-treated bacteria (non-diabetic) and bacteria from diabetic Enrofloxacin-treated 
mice labeled as Enrofloxacin-treated bacteria (diabetic).  All splenocyte cultures with 
bacteria displayed significant differences from those without bacteria. All data was pooled 
from 3 independent experiments (n=8/group; from 3-4 different breeders).  All data were 
assessed for statistical significance using multiple Student's t tests corrected using FDR. Data 
are plotted as mean with SEM.  
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Figure 6 
Effect of culture of G9Cα-/-NOD mice splenocytes with small intestinal bacteria from 
untreated or enrofloxacin-treated A22Cα-/-PI2-/-NOD mice.  Intracellular IFN-gamma was 
measured in CD8+T-cells (A; gated from TCRβ+CD19-CD4-), CD11b+cells (B; gated from 
TCRβ-CD19-IAg7+CD11c-F480+) and CD11c+cells (C; gated from TCRβ-CD19-
IAg7+CD11b-F480-).  Average baseline levels of splenocyte IFN-gamma-producing cells, 
cultured without bacteria, which were similar in all treatment groups are shown by the dotted 
line.  The labeling beneath the graphs represent the origin of the bacteria - Bacteria from 
Non-Enrofloxacin treated mice labeled as Non-Enrofloxacin-treated bacteria, bacteria from 
non-diabetic Enrofloxacin-treated mice labeled as Enrofloxacin-treated bacteria (non-
diabetic) and bacteria from diabetic Enrofloxacin-treated mice labeled as Enrofloxacin-
treated bacteria (diabetic). All splenocyte cultures with bacteria displayed significant 
differences from those without bacteria. All data was pooled from 2 independent experiments 
(n=6/group).  All data were assessed for statistical significance using multiple Student's t tests 
corrected using FDR.  Data are presented as mean with SEM.  
 
Figure 7 
Effect of enrofloxacin treatment on non-TCR restricted polyclonal NOD mice.  A; Principal 
Component of Analysis (PCoA) plot of β-diversity from fecal bacteria of 3- and 6-week old 
NOD mice that were untreated or treated with enrofloxacin (n=4-7 mice).  B; Altered 
microbiota composition expressed as a percentage of relative abundance of bacterial genus.  
C; Absolute number of Insulin B-15-23-reactive CD8+T-cells gated from live single 
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TCRβ+CD4-CD19-CD11b-CD11c- cells.  D; Absolute number of CD69+ Insulin B-15-23-
reactive CD8+T-cells gated as in (C) prior to subsequently gating on CD69.  E-G; Frequency 
of IFN-gamma producing CD8+T-cells (E; gated from TCRβ+CD19-CD4-)), CD11c+cells 
(F; gated from TCRβ-CD19-IAg7+CD11b-F480-) and CD11b+cells (G; gated from TCRβ-
CD19-IAg7+CD11c-F480+).  All data was pooled from 2 independent experiments 
(n=8/group).  All statistical analyses were conducted using a Student’s t test.  Data are 
presented as mean ± SEM. 
 
Supplementary Figure Legends 
 
Supplementary Figure 1 
Frequencies of CD4+T-cells, CD8+T-cells and Treg cells.  A-B; CD4+ and CD8+T-cell 
frequency in lymphoid tissues (Spleen, Pancreatic draining lymph node (PLN), mesenteric 
lymph node (MLN) or Peyer’s patches (PP) of A22Cα-/-PI2-/-NOD mice, gated from total live 
single cells. C; Frequency of CD4+FoxP3+ Treg cells in the PLN or PP, gated from live 
single TCRβ+CD19-CD8-cells.  Data were pooled from 2 independent experiments (n=10).  
Statistical analysis was performed using Student's t test. Data shown are plotted as mean with 
SEM. 
 
Supplementary Figure 2 
CD8+T-cell staining with insulin-B15-23 tetramer. A; Representative Insulin B15-23-
tetramer (H-2Kd-LYLVCGERG BV421 tetramer) staining of CD8+T-cells from the PLN, 
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including a negative control (H-2Kd-AYAAAAAAV-BV421 tetramer) and a positive control 
(cells from G9Cα-/-NOD).  B; Representative CD69 staining from Insulin-B15-23-reactive 
CD8+T-cells from PLN and PP gated from live single TCRβ+CD19-CD4-CD8+Tetramer+T-
cells.  C-D; CD69 expression in Insulin B15-23 Tetramer- CD8+T-cells from PLN (C) and 
PP (D).  E; Representative CD44 and CD62L staining from Insulin-B15-23-reactive CD8+T-
cells from PLN and PP gated from live single TCRβ+CD19-CD4-CD8+Tetramer+T-cells.  F-
G; CD44+CD62L- expression in Insulin B15-23 Tetramer- CD8+T-cells from PLN (F) and 
PP (G).  Data were pooled from 2 independent experiments (n=10).  Statistical analysis was 
performed using Student's t test. Data shown are plotted as mean with SEM.  
 
Supplementary Figure 3 
CD8+T-cell staining with anti-TCRV antibodies. TCRV repertoire differences in total T-
cell population in A22Cα-/-PI2-/-NOD mice by enrofloxacin treatment in the PLN (A) or PP 
(B) of age-matched mice (6 to10-week-old).  Enrofloxacin-treated mice are shown as those 
that developed diabetes and those that did not.  Statistical analysis was performed using 
Student's t test. Data shown are plotted as mean with SEM. 
 
Supplementary Figure 4 
Representative FACS plots and FMOs for Insulin B15-23-reactive CD8+T-cell staining with 
anti-TCRV antibodies of age-matched A22Cα-/-PI2-/-NOD mice (6-week-old) by 
enrofloxacin treatment.  TCRV (A), TCRV6 (B) TCRV8 (C), TCRV11 (D) and 
TCRV12 (E) cells in the PP are shown. All cells were gated on from live single 
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TCRβ+CD8+CD4-CD19-InsulinB15-23 tetramer+ cells prior to gating on the cells 
expressing the particular TCRV chain.   
 
Supplementary Figure 5 
Direct ex vivo assessment of antigen presenting cell phenotype in untreated and enrofloxacin-
treated A22Cα-/-PI2-/-NOD mice (n=10). A-D; Representative CD103+ staining gated from 
live single CD19-TCR-IAg7+CD11b-F480- cells (A) or CD19-TCR-IAg7+CD11c-F480+ 
cells (B), with cell counts (C-D respectively). E-F; Representative IFN-gamma+ staining 
gated from live single CD19-TCR-IAg7+CD11b-F480-cells (E) or CD19-TCR-
IAg7+CD11c-F480+ cells (F). G-H; Representative IL10+ staining gated from live single 
CD19-TCR-IAg7+CD11b-F480- cells (G) or CD19-TCR-IAg7+CD11c-F480+ cells (H).  I-
L; Cell counts for IFN-gamma+ CD11c+ cells (I) and CD11b+ cells (J) as well as IL10+ 
CD11c+ cells (K) and CD11b+ cells (L).  All statistical analyses were conducted using a 
Student’s t test. All data were pooled from 2 independent experiments with n=10, Data are 
presented as mean with SEM. ND (non-detected). 
 
Supplementary Figure 6 
Direct ex vivo assessment of CD11b+CD11c+ cell phenotype and B-cell IgA frequency in PP 
of untreated and enrofloxacin-treated A22Cα-/-PI2-/-NOD mice. A; Frequency of 
CD11b+CD11c+CD103+ cells gated from live single CD19-TCR-IAg7+CD11b+CD11c+ 
cells. B-C; Frequency of CD11b+CD11c+IFNgamma+ cells (B) and CD11b+CD11c+IL10+ 
cells (C) gated as in A. D; Frequency of CD19+IgA+ B-cells gated from live single TCR-
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IAg7+CD19+ cells.  All data were pooled from 2 independent experiments with n=10, Data 
are presented as mean with SEM. 
 
Supplementary Figure 7  
Proliferation of insulin-reactive T cells to peptide presentation by APC from enrofloxacin 
treated and untreated mice.  Representative FACS plots of CFSE-labeled G9 CD8+T-cells 
showing proliferation in response to Insulin B15-23 peptide presentation by either CD11c+ 
cells (A) or CD11b+ cells (B) isolated from enrofloxacin treated or untreated A22Cα-/-PI2-/-
NOD mice. 
 
Supplementary Figure 8 
CD69 and intracellular IFNgamma+ CD8 T cells cultured in the presence of enrofloxacin.  
G9 CD8+T-cells were co-cultured with irradiated NOD BMDCs for 72 hours in the presence 
of Insulin B15-23 peptide with or without the addition of different doses of enrofloxacin. 
Live single cell CD8+T-cells were gated prior to CD69 (A) or IFN-gamma (B) staining. 
Background values (cells without peptide) were subtracted from all data with peptide.  All 
statistical analyses were conducted using a multiple t test.  Data are presented as mean with 
SEM. 
 
Supplementary Figure 9 
Alpha diversity and microbial composition before enrofloxacin treatment at 3 weeks of age, 
and after treatment at 6 weeks of age in the groups of A22Cα-/-PI2-/-NOD mice shown by 
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enrofloxacin treatment.  Fecal bacteria of 3 and 6-week old A22Cα-/-PI2-/-NOD mice were 
sequenced from untreated mice or enrofloxacin-treated (before treatment at 3 weeks of age 
and after treatment at 6 weeks of age). Samples at 3-weeks of age were collected prior to 
dividing litters and the start of antibiotic treatment. A; α-diversity as assessed by Chao 
richness.  B; Principal Component of Analysis (PCoA) plot of β-diversity from fecal bacteria 
of 3 and 6-week old A22Cα-/-PI2-/-NOD mice that were untreated or treated from 3 weeks of 
age. Data shown in A were assessed for statistical significance using a Student's t test. 
Analysis of similarities (ANOSIM) was used to analyze -diversity of taxonomic families of 
gut microbiota (B). 
 
Supplementary Figure 10 
Intracellular IFN-gamma+CD8+T-cells in splenocytes from 6 or 10-week-old A22Cα-/-PI2-/-
NOD mice cultured with bacteria from untreated and enrofloxacin-treated (both non-diabetic 
and diabetic) mice.  Data show representative staining of IFN-gamma+CD8+T-cells (gated 
from TCRβ+CD19-CD4-cells) following culture and then stimulation with PMA and 
ionomycin in the presence of monensin.  Each row represents the mouse treatment group at 6 
weeks (top 2 rows) and 10 weeks (bottom 2 rows).  Each column shows the mouse group 
from which the bacteria were derived. 
 
Supplementary Figure 11 
IFN-gamma+CD11b+cells from splenocytes from 6 or 10-week-old A22Cα-/-PI2-/-NOD mice 
cultured with bacteria from untreated and enrofloxacin-treated (both non-diabetic and 
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diabetic) mice.  Data show representative staining of IFN-gamma+CD11b+cells (gated from 
TCRβ-CD19-IAg7+CD11c-F480+) following culture and then stimulation with PMA and 
ionomycin in the presence of monensin.  Each row represents the mouse treatment group at 6 
weeks (top 2 rows) and 10 weeks (bottom 2 rows).  Each column shows the mouse group 
from which the bacteria were derived.. 
 
Supplementary Figure 12 
IFN-gamma+CD11c+cells from splenocytes from 6 or 10-week-old A22Cα-/-PI2-/-NOD mice 
cultured with bacteria from untreated and enrofloxacin-treated (both non-diabetic and 
diabetic) mice.  Data show representative staining of IFN-gamma+CD11c+cells (gated from 
TCRβ-CD19-IAg7+CD11b-F480-) following culture and then stimulation with PMA and 
ionomycin in the presence of monensin.  Each row represents the mouse treatment group at 6 
weeks (top 2 rows) and 10 weeks (bottom 2 rows).  Each column shows the mouse group 
from which the bacteria were derived.. 
 
Supplementary Figure 13 
IFN-gamma secretion from CD8+T-cells, CD11b+cells and CD11c+cells from G9Cα-/-NOD 
splenocytes stimulated with bacteria from untreated and enrofloxacin-treated (both non-
diabetic and diabetic) mice.  Data show representative staining of IFN-gamma+ CD8+T-cells 
(A; gated from TCRβ+CD19-CD4-cells), CD11b+cells (B; gated from TCRβ-CD19-
IAg7+CD11c-F480+) and CD11c+cells (C; gated from TCRβ-CD19-IAg7+CD11b-F480-) 
following culture and then stimulation with PMA and ionomycin in the presence of 
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monensin.  Each row represents the mouse treatment group at 6 weeks (top 2 rows) and 10 
weeks (bottom 2 rows).  Each column shows the mouse group from which the bacteria were 
derived.. 
 
Supplementary Figure 14 
Principal Component of Analysis (PCoA) plot of β-diversity from fecal bacteria of 6-week 
old A22Cα-/-PI2-/-NOD mice and NOD mice that were untreated or enrofloxacin-treated from 
3 weeks of age. Analysis of similarities (ANOSIM) was used to analyze -diversity of 
taxonomic families of gut microbiota. All groups were found to be significantly different to 
each other (p=0.008). 
 
Supplementary Figure 15 
CD8+T-cell staining with insulin-B15-23 tetramer of NOD mice treated or untreated with 
enrofloxacin. A; Representative Insulin B15-23-tetramer (H-2Kd-LYLVCGERG BV421 
tetramer) staining of CD8+T-cells, including a negative control (H-2Kd-AYAAAAAAV-
BV421 tetramer) and a positive control (G9Cα-/-NOD cells stained using H-2Kd-
LYLVCGERG-BV421 tetramer.  B; Proportion of insulin-B15-23 tetramer+CD8+T-cells 
(gated from live single TCRβ+CD19-CD4-CD8+ cells); C; Insulin B15-23-tetramer MFI D; 
CD69 staining from Insulin-B15-23-reactive CD8+T-cells gated from live single 
TCRβ+CD19-CD4-CD8+Tetramer+T-cells.  E; Representative CD69 staining from insulin-
B15-23 tetramer+ CD8+ T-cells.  Data were pooled from 2 independent experiments (n=10).  
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Statistical analysis was performed using Student's t test. Data shown are plotted as mean with 
SEM. 
 
Supplementary Figure 16 
CD8+T-cell staining with IGRP-206-214 tetramer of enrofloxacin-treated and untreated NOD 
mice. A; Representative IGRP 206-214-tetramer (H-2kd-VYLKTNVFL-APC) staining of 
CD8+T-cells, including a negative control (H-2Kd-AYAAAAAAV-APC) and a positive 
control (NY8.3NOD cells stained using H-2kd-VYLKTNVFL-APC tetramer).  B-C; Absolute 
count and frequency of IGRP 206-214-reactive CD8+T-cells gated from live single 
TCRβ+CD19-CD4-CD8+ cells.  D; IGRP 206-214-tetramer MFI.  E; CD69 staining from 
IGRP-206-214-reactive CD8+T-cells gated from live single TCRβ+CD19-CD4-
CD8+Tetramer+T-cells.  F-G; Frequency and absolute number of CD69+ IGRP 206-214-
reactive CD8+T-cells. Data were pooled from 2 independent experiments (n=10).  Statistical 
analysis was performed using Student's t test. Data shown are plotted as mean with SEM. 
 
Supplementary Figure 17 
Representative IFN-gamma staining from enrofloxacin-treated and untreated NOD mice (6-
weeks of age).  A; CD8+T-cells (gated from live single TCRβ+CD19-CD4-cells).  B; 
CD11c+cells (gated from live single TCRβ-CD19-IAg7+CD11b-F480- cells. C; CD11b+cells 
(gated from live single TCRβ-CD19-IAg7+CD11c-F480+ cells). 
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Supplementary Table 1 – Summary of mouse models used 
 
 
NOD; Non-Obese Diabetic mouse, PI1; Proinsulin 1, PI2; Proinsulin 2, TCR; T-cell Receptor; TRAV; TCRȽ chain, TRBV; TCRȾ 
chain, TRAJ; TCRȽ joining chain, TRBJ; TCRȾ joining chain. 
 
 
Strain TCRȽ chain TCRȾ chain Insulin B15-23 
reactive CD8+ T-cells 
Proinsulin 
expression 
Diabetes 
incidence 
References Figures 
A22Cα-/-PI2-/-NOD TRAV8-1 
TRAJ9 
Any 
endogenous 
TCRȾ chain Up to 3% of the total CD8+ T-cell population PI2 deficient; PI1 sufficient 25-40% in males (34) All (except Fig. 1D, Fig. 6-7, Supp Fig. 8, Supp 
Fig. 13, Supp Fig. 
15-17) 
G9Cα-/-PI2-/-NOD TRAV8-1 
TRAJ9 
TRBV19 
TRBJ2-3 
All T-cells PI2 deficient; 
PI1 sufficient 
~25-40% 
in males 
(36) Fig. 1D 
G9Cα-/-NOD TRAV8-1 
TRAJ9 
TRBV19 
TRBJ2-3 
All T-cells PI2 
sufficient;  
PI1 sufficient 
None (35) Fig. 3G-H, Fig. 6, 
Supp Fig. 2A, 
Supp Fig. 8, Supp 
Fig. 13 
NOD Any 
endogenous 
TCRȽ chain Any endogenous TCRȾ chain Less than 1% of the total CD8+ T-cell population PI2 sufficient;  PI1 sufficient 20-30% in males (34) Fig. 7, Supp Fig. 8, Supp Fig. 14-17 
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